Zhaoyan Pharmaceutical (06127) expects net profit to increase by about 884.9% to 1377.4% year-on-year in the first half of the year

According to the Zhitong Finance App, Zhaoyan New Pharmaceutical (06127) announced that it expects to achieve operating revenue of about RMB 669 million to RMB 739 million from January to June 2026, an increase of about 0% to 10.5% over the previous year. Net profit attributable to shareholders of listed companies is expected to be approximately RMB 600 million to RMB 900 million from January to June 2026, an increase of about 884.9% to 1377.4% over the previous year.

During the reporting period, the rise in the biological asset market price was compounded by its own natural growth and value addition. Two factors drove positive changes in its fair value and contributed positively to the company's performance. Furthermore, during the reporting period, the company's laboratory continued to maintain a good and stable operating state. Despite the overall recovery of the industry, due to delays in fierce competition in the early stages, revenue for the current period only increased slightly, and the gross profit level has yet to be recovered.